

REMARKS

Applicants respectfully request that the deletion of Claims 16, 17, 23, 24 and 28 and the foregoing amendment to the Claims 1, 4-15, 18-22, 25, 27 and 29-30 be made prior to examination of the present application.

Respectfully submitted,

Date

Dec 12, 2001

By



FOLEY & LARDNER
Customer Number: 22428



22428


PATENT TRADEMARK OFFICE

Telephone: (202) 672-5427
Facsimile: (202) 672-5399

Bernhard D. Saxe
Attorney for Applicant
Registration No. 28,665

VERSION WITH MARKINGS TO SHOW CHANGES MADE

1. (Amended) A chemical compound of formula (I):



wherein:

R₁ and R₂ are independently selected from hydrogen and alkyl;

R₃ is alkyl;

R₄, R₆ and R₇ are independently selected from hydrogen, halogen, hydroxy, alkyl, aryl, amino, alkylamino, dialkylamino, alkoxy, aryloxy, alkylthio, alkylsulfoxyl, alkylsulfonyl, nitro, carbonitrile, carbo-alkoxy, carbo-aryloxy and carboxyl;

R₅ is selected from hydrogen, halogen, hydroxy, alkyl, aryl, amino, alkylamino, dialkylamino, alkoxy, aryloxy, alkylthio, alkylsulfoxyl, alkylsulfonyl, nitro, carbonitrile, carbo-alkoxy, carbo-aryloxy and carboxyl; and

A is a 5- or 6-membered partially unsaturated or aromatic heterocyclic ring or a 5- or 6- membered partially unsaturated carbocyclic ring,

wherein if A is a 6-membered partially unsaturated carbocyclic ring then at least one of R₄ to R₇ is other than hydrogen,

[and] or a pharmaceutically acceptable salt[s], addition compound[s and] or prodrug[s] thereof.

4. (Amended) A compound according to claim 1, [2 or 3] wherein R₃ is lower alkyl.

5. (Amended) A compound according to claim 1, [2 or 3] wherein R₃ is methyl.

6. (Amended) A compound according to [any preceding] claim 1, wherein

R₄ is selected from hydrogen, halogen, alkyl and alkoxy.

7. (Amended) A compound according to [any preceding] claim 1, wherein R₄ is hydrogen.

8. (Amended) A compound according to [any preceding] claim 1, wherein R₆ is selected from hydrogen and halogen.

9. (Amended) A compound according to [any preceding] claim 1, wherein R₇ is selected from hydrogen, halogen and alkoxy.

10. (Amended) A compound according to [any preceding] claim 1, wherein A is a 5- membered ring.

11. (Amended) A compound according to [any preceding] claim 1, wherein A is partially unsaturated.

12. (Amended) A compound according to [any preceding] claim 1, wherein A contains a heteroatom selected from N, O and S.

13. (Amended) A compound according to [any of] claim[s] 1₂ [to 9] wherein A is a 5- membered partially unsaturated carbocyclic ring, a 5- membered partially unsaturated or aromatic heterocyclic ring or a 6- membered partially unsaturated carbocyclic ring.

14. (Amended) A compound according to [any of] claim[s] 1₂ [to 9] wherein A is selected from cyclopentenyl, cyclohexenyl, thiacyclohexenyl and thienyl.

15. (Amended) A compound according to claim 1 which is selected from the group consisting of (S)-1-(7,8-difluoro-1,2,3,4-tetrahydrocyclopent[b]indol-4-yl)-2-propylamine, (S)-1-(7-fluoro-1,2,3,4-tetrahydrocyclopent[b]indol-4-yl)-2-propylamine, (S)-1-(8-chloro-1,2,3,4-tetrahydrocyclopent[b]indol-4-yl)-2-propylamine, (S)-1-(6-methoxy-1,2,3,4-tetrahydrocyclopent[b]indol-4-yl)-2-propylamine, (S)-1-(7-fluoro-6-methoxy-1,2,3,4-tetrahydrocyclopent[b]indol-4-yl)-2-propylamine, (S)-1-(7-fluoro-8-methoxy-1,2,3,4-tetrahydrocyclopent[b]indol-4-yl)-2-propylamine, (S)-1-(8-chloro-7-

fluoro-1,2,3,4-tetrahydrocyclopent[*b*]indol-4-yl)-2-propylamine, (*S*)-1-(1,2,3,4-tetrahydrocyclopent[*b*]indol-4-yl)-2-propylamine and (*R*)-1-(1,2,3,4-tetrahydrocyclopent[*b*]indol-4-yl)-2-propylamine.

18. (Amended) A [use] method according to claim [17] 25 wherein the disorders of the central nervous system are selected from the group consisting of depression, atypical depression, bipolar disorders, anxiety disorders, obsessive-compulsive disorders, social phobias or panic states, sleep disorders, sexual dysfunction, psychoses, schizophrenia, migraine and other conditions associated with cephalic pain or other pain, raised intracranial pressure, epilepsy, personality disorders, age-related behavioural disorders, behavioural disorders associated with dementia, organic mental disorders, mental disorders in childhood, aggressivity, age-related memory disorders, chronic fatigue syndrome, drug and alcohol addiction, obesity, bulimia, anorexia nervosa and premenstrual tension.

19. (Amended) A [use] method according to claim [17] 25 wherein the damage to the central nervous system is by trauma, stroke, neurodegenerative diseases or toxic or infective CNS diseases.

20. (Amended) A [use] method according to claim 19 wherein said toxic or infective CNS disease is encephalitis or meningitis.

21. (Amended) A [use] method according to claim [17] 25 wherein the cardiovascular disorder is thrombosis.

22. (Amended) A [use] method according to claim [17] 25 wherein the gastrointestinal disorder is dysfunction of gastrointestinal motility.

25. (Amended) A method of treatment of [any of the disorders set out in claims 17 to 22] disorders of the central nervous system; damage to the central nervous system; cardiovascular disorders; gastrointestinal disorders; diabetes insipidus, and sleep apnea, comprising administering to a patient in need of such treatment an effective dose of a compound of formula (I) as set out in [any one of] claim[s] 1 [to 15].

27. (Amended) A method according to claim 25 [or 26] wherein said treatment is prophylactic treatment.

29. (Amended) A pharmaceutical composition comprising a compound of formula (I) as set out in [any one of] claim[s] 1, [to 15] in combination with a pharmaceutically acceptable carrier or excipient.

30. (Amended) A method of making a pharmaceutical composition, [according to claim 29] comprising combining a compound of formula (I) as set out in [any one of] claim[s] 1 [to 15] with a pharmaceutically acceptable carrier or excipient.